Literature DB >> 24412053

Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III.

Michela Visani1, Dario de Biase2, Gianluca Marucci3, Serenella Cerasoli4, Evandro Nigrisoli4, Maria Letizia Bacchi Reggiani5, Fiorenzo Albani6, Agostino Baruzzi6, Annalisa Pession1.   

Abstract

Several biomarkers have been proposed as useful parameters to better specify the prognosis or to delineate new target therapy strategies for glioblastoma patients. MicroRNAs could represent putative target molecules, considering their role in tumorigenesis, cancer progression and their specific tissue expression. Although several studies have tried to identify microRNA signature for glioblastoma, a microRNA profile is still far from being well-defined. In this work the expression of 19 microRNAs (miR-7, miR-9, miR-9∗, miR-10a, miR-10b, miR-17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, miR-182, miR-221, miR-222, miR-330, miR-519d) was evaluated in sixty formalin-fixed and paraffin-embedded glioblastoma samples using a locked nucleic acid real-time PCR. Moreover, a comparison of miRNA expressions was performed between primary brain neoplasias of different grades (grades IV-I). The analysis of 14 validated miRNA expression in the 60 glioblastomas, using three different non-neoplastic references as controls, revealed a putative miRNA signature: mir-10b and miR-21 were up-regulated, while miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330 were down-regulated in glioblastomas. Comparing miRNA expression between glioblastoma group and gliomas of grades I-III, 3 miRNAs (miR-10b, mir-34a and miR-101) showed different regulation statuses between high-grade and low-grade tumors. miR-10b was up-regulated in high grade and significantly down-regulated in low-grade gliomas, suggesting that could be a candidate for a GBM target therapy. This study provides further data for the identification of a miRNA profile for glioblastoma and suggests that different-grade neoplasia could be characterized by different expression of specific miRNAs.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain neoplasia; Glioblastoma; Low-grade brain tumors; MicroRNA; Real-time PCR

Mesh:

Substances:

Year:  2013        PMID: 24412053      PMCID: PMC5528554          DOI: 10.1016/j.molonc.2013.12.010

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  62 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Transcription, genomes, function.

Authors:  R J Cho; M J Campbell
Journal:  Trends Genet       Date:  2000-09       Impact factor: 11.639

3.  Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

Authors:  Ralph P Ermoian; Constance S Furniss; Kathleen R Lamborn; Daniel Basila; Mitchel S Berger; Alexander R Gottschalk; M Kelly Nicholas; David Stokoe; Daphne A Haas-Kogan
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

Review 4.  microRNAs as oncogenes and tumor suppressors.

Authors:  Baohong Zhang; Xiaoping Pan; George P Cobb; Todd A Anderson
Journal:  Dev Biol       Date:  2006-08-16       Impact factor: 3.582

Review 5.  Insulin-like growth factor type I biology and targeting in malignant gliomas.

Authors:  J Trojan; J-F Cloix; M-Y Ardourel; M Chatel; D D Anthony
Journal:  Neuroscience       Date:  2007-02-21       Impact factor: 3.590

6.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.

Authors:  Jennifer A Chan; Anna M Krichevsky; Kenneth S Kosik
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

7.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

8.  Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.

Authors:  Núria de la Iglesia; Genevieve Konopka; Kah-Leong Lim; Catherine L Nutt; Jacqueline F Bromberg; David A Frank; Paul S Mischel; David N Louis; Azad Bonni
Journal:  J Neurosci       Date:  2008-06-04       Impact factor: 6.167

9.  microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.

Authors:  Benjamin Kefas; Jakub Godlewski; Laurey Comeau; Yunqing Li; Roger Abounader; Michael Hawkinson; Jeongwu Lee; Howard Fine; E Antonio Chiocca; Sean Lawler; Benjamin Purow
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  50 in total

1.  Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform.

Authors:  Menha Swellam; Lobna Ezz El Arab; Amr S Al-Posttany; Samy B Said
Journal:  J Neurooncol       Date:  2019-08-17       Impact factor: 4.130

Review 2.  MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells.

Authors:  Jeffrey V Brower; Paul A Clark; Will Lyon; John S Kuo
Journal:  Neurochem Int       Date:  2014-06-14       Impact factor: 3.921

3.  Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.

Authors:  Wen Cheng; Xiufang Ren; Chuanbao Zhang; Sheng Han; Anhua Wu
Journal:  J Neurooncol       Date:  2017-01-16       Impact factor: 4.130

4.  miR-217-casein kinase-2 cross talk regulates ERK activation in ganglioglioma.

Authors:  Atreye Majumdar; Fahim Ahmad; Touseef Sheikh; Reshma Bhagat; Pankaj Pathak; Shanker Datt Joshi; Pankaj Seth; Vivek Tandon; Manjari Tripathi; P Saratchandra; Chitra Sarkar; Ellora Sen
Journal:  J Mol Med (Berl)       Date:  2017-08-25       Impact factor: 4.599

5.  MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.

Authors:  Mónica Rivera-Díaz; Miguel A Miranda-Román; Daniel Soto; Mario Quintero-Aguilo; Humberto Ortiz-Zuazaga; María J Marcos-Martinez; Pablo E Vivas-Mejía
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 6.  MicroRNA as potential biomarkers in Glioblastoma.

Authors:  Zammam Areeb; Stanley S Stylli; Rachel Koldej; David S Ritchie; Tali Siegal; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor
Journal:  J Neurooncol       Date:  2015-09-21       Impact factor: 4.130

7.  Expression of microRNAs in tumors of the central nervous system in pediatric patients in México.

Authors:  Pilar Eguía-Aguilar; Lisette Gutiérrez-Castillo; Mario Pérezpeña-Díazconti; Jeanette García-Chéquer; Jorge García-Quintana; Fernando Chico-Ponce de León; Luis Gordillo-Domínguez; Samuel Torres-García; Francisco Arenas-Huertero
Journal:  Childs Nerv Syst       Date:  2017-08-16       Impact factor: 1.475

Review 8.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

9.  Serum miR-182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats.

Authors:  Merricka C Livingstone; Natalie M Johnson; Bill D Roebuck; Thomas W Kensler; John D Groopman
Journal:  Mol Carcinog       Date:  2019-08-02       Impact factor: 4.784

10.  MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.

Authors:  Hirosha Geekiyanage; Evanthia Galanis
Journal:  Mol Oncol       Date:  2016-07-28       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.